Keay Nakae
Stock Analyst at Chardan Capital
(3.54)
# 805
Out of 4,670 analysts
194
Total ratings
31.41%
Success rate
11.32%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABUS Arbutus Biopharma | Maintains: Buy | $4.5 → $5 | $3.51 | +42.45% | 11 | Nov 20, 2024 | |
| ALUR Allurion Technologies | Downgrades: Neutral | n/a | $0.43 | - | 4 | Nov 14, 2024 | |
| SLN Silence Therapeutics | Maintains: Buy | $55 | $7.01 | +684.59% | 9 | Nov 14, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $1.25 | $0.77 | +62.63% | 8 | Nov 13, 2024 | |
| FEMY Femasys | Maintains: Buy | $10 → $8 | $1.05 | +661.90% | 10 | Nov 13, 2024 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $5.77 | +246.62% | 7 | Nov 13, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $50 | $29.69 | +68.41% | 7 | Nov 13, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $65 | $43.25 | +50.29% | 12 | Nov 13, 2024 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $6.50 | +115.38% | 14 | Nov 7, 2024 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $25 | $3.13 | +698.72% | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 | $244.89 | +22.50% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 | $2.98 | +7,953.69% | 11 | Aug 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.72 | +248.84% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.79 | +663.36% | 6 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 | $18.54 | +223.62% | 15 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $2.64 | +89.39% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 | $3.62 | -30.94% | 12 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.43 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $10.11 | -40.65% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.54 | +3,571.75% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $9.48 | +480.17% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $18.38 | -45.59% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $16.00 | +446.88% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $0.91 | +1,332.66% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $155 → $40 | $2.71 | +1,376.01% | 2 | Jun 30, 2020 |
Arbutus Biopharma
Nov 20, 2024
Maintains: Buy
Price Target: $4.5 → $5
Current: $3.51
Upside: +42.45%
Allurion Technologies
Nov 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Silence Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $55
Current: $7.01
Upside: +684.59%
Seres Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $1.25
Current: $0.77
Upside: +62.63%
Femasys
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.05
Upside: +661.90%
Orchestra BioMed Holdings
Nov 13, 2024
Maintains: Buy
Price Target: $20
Current: $5.77
Upside: +246.62%
Dyne Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $50
Current: $29.69
Upside: +68.41%
Avidity Biosciences
Nov 13, 2024
Maintains: Buy
Price Target: $65
Current: $43.25
Upside: +50.29%
Coya Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $14
Current: $6.50
Upside: +115.38%
SAB Biotherapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $25
Current: $3.13
Upside: +698.72%
Nov 1, 2024
Maintains: Buy
Price Target: $300
Current: $244.89
Upside: +22.50%
Aug 23, 2024
Maintains: Buy
Price Target: $240
Current: $2.98
Upside: +7,953.69%
Aug 9, 2024
Maintains: Buy
Price Target: $6
Current: $1.72
Upside: +248.84%
Aug 7, 2024
Maintains: Buy
Price Target: $7 → $6
Current: $0.79
Upside: +663.36%
Jul 17, 2024
Maintains: Buy
Price Target: $60
Current: $18.54
Upside: +223.62%
Jun 3, 2024
Maintains: Buy
Price Target: $5
Current: $2.64
Upside: +89.39%
May 10, 2024
Maintains: Buy
Price Target: $2.5
Current: $3.62
Upside: -30.94%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $10.11
Upside: -40.65%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.54
Upside: +3,571.75%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $9.48
Upside: +480.17%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $18.38
Upside: -45.59%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $16.00
Upside: +446.88%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $0.91
Upside: +1,332.66%
Jun 30, 2020
Downgrades: Neutral
Price Target: $155 → $40
Current: $2.71
Upside: +1,376.01%